

RECEIVED  
CENTRAL FAX CENTER

DEC 14 2006

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR § 1.97(b), 1.97(c), or 1.97(d)			Attny. Docket No. 2003B047
In Re Application of: David R. Lumgair, Jr. et al.			
U.S. Serial No. 10/603,716	Filing Date June 25, 2003	Examiner In Suk C. Bullock	Group Art Unit 1764

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## 37 CFR § 1.97(b)

- ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

## 37 CFR § 1.97(c)

- ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of:

1. a Final Action under § 1.113,
2. a Notice of Allowance under § 1.311, or
3. an action that otherwise closes prosecution in the application,

and is accompanied by either:

- ☐ the fee as set forth in § 1.17(p), or
- ☐ the following statement under § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

## 37 CFR § 1.97(d)

- ☐ The Information Disclosure Statement submitted herewith is being filed after a Final Action under § 1.113, a Notice of Allowance under § 1.311, or an action that otherwise closes prosecution in the application, but before, or simultaneously with, the payment of the issue fee. Submitted herewith is the fee as set forth in § 1.17(p) and the following statement under 37 CFR § 1.97(e)(1): each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Applicant hereby request consideration of the Information Disclosure Statement, USPTO form 1449, submitted herewith.

☐ Legible copies of references are enclosed where necessary.

☐ This application is a:  
☐ Continuation / Divisional,  
☐ Continuation-in-Part,

of U.S.S.N. \_\_\_\_\_ Copies of the cited references are  
☐ enclosed; ☐ not enclosed. References are available in the parent application(s) if not enclosed.

The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment, to Deposit Account Number 05-1712. A duplicate copy of this form is enclosed.

Respectfully submitted,



Melinda R. Michalerya  
Attorney for the Applicant  
U. S. Registration No. 59,654

Date

12/14/06

ExxonMobil Chemical Company  
Law Technology  
P.O. Box 2149  
Baytown, Texas 77522-2149  
(281) 834-5145 Office  
(281) 834-2495 Facsimile

SHEET 1 OF 1

## INFORMATION DISCLOSURE STATEMENT

*(Use several sheets if necessary)*

ATTY. DOCKET NO.

**2003B047**

**SERIAL NO.**

**10/603,716**

**APPLICANT**

**David R. LUMGAIR, Jr. et al.**

FILING DATE

**June 25, 2003**

**GROUP**

1764

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages of Publication, Etc.)

EXAMINER

DATE CONSIDERED

\*EXAMINER:

Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next comment to applicant